JAMA Intern Med:PEG溶液疗法治疗急性肝性脑病效果好

2014-11-10 佚名 生物谷

近日,来自贝勒大学医学中心的科学家通过研究指出,进行结肠镜检查前用于清理病人肠道的常见药物或许是未来治疗急性肝性脑病(acute hepatic encephalopathy,HE)患者的标准疗法,急性肝性脑病是影响二分之一肝硬化病人的脑错乱疾病,相关研究刊登于国际杂志JAMA Internal Medicine上。 Robert Rahimi博士表示,本文研究中我们对比了当前HE疗法-乳果

近日,来自贝勒大学医学中心的科学家通过研究指出,进行结肠镜检查前用于清理病人肠道的常见药物或许是未来治疗急性肝性脑病(acute hepatic encephalopathy,HE)患者的标准疗法,急性肝性脑病是影响二分之一肝硬化病人的脑错乱疾病,相关研究刊登于国际杂志JAMA Internal Medicine上。

Robert Rahimi博士表示,本文研究中我们对比了当前HE疗法-乳果糖疗法同携带聚乙二醇3350电解质溶液(PEG)疗法(GoLYTELY?)的差别,GoLYTELY?是一种口服药,用于患者在结肠镜检查前的肠道清理中。从20世纪60年代开始乳果糖疗法都已经被公认为是治疗患者疾病的标准疗法。

本文研究中,研究者将受急性肝性脑病折磨的50名患者分为两组,每组25人,其中一组接受乳果糖标准疗法,另外一组进行PEG溶液新型疗法,结果显示,相比进行乳果糖疗法患者(52%),PEG组患者的症状得到了明显改善(92%),而且PEG组患者无副作用病例报告;此外接受PEG治疗的患者住院期短于乳果糖组患者。

研究者Rahimi说道,平均来讲入院治疗急性肝性脑病的治疗期在5天左右,而利用PEG溶液疗法治疗急性肝性脑病患者仅需一天即可明显缓解患者的症状,从而明显减少患者的住院时间及经济上的负担。急性肝性脑病在肝硬化病人中的发病比例高达45%,患者经常需要入院进行治疗。

当前的乳果糖疗法中的乳果糖是一种泻药,其在治疗肝性脑病上已经有将近50年了;很多年以来,肝脏病学家推测,乳果糖或许是通过把氨转化成为铵,从而来抑制氨进入到患者的血液中去,进而使得肝性脑病患者的症状得到缓解。而本文研究中,研究者指出,PEG溶液疗法或许在这几年中将成为治疗急性肝性脑病的标准疗法,然而当前仍需要更多的研究来阐明PEG溶液疗法的安全性和有效性。

原始出处

Rahimi RS1, Singal AG2, Cuthbert JA3, Rockey DC4.Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy The HELP Randomized Clinical Trial.JAMA Intern Med. 2014 Nov 1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725672, encodeId=73b31e2567233, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Dec 06 10:05:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666382, encodeId=2f46166638255, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Dec 12 15:05:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533477, encodeId=647a15334e752, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606320, encodeId=68bc16063206a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=)]
    2014-12-06 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725672, encodeId=73b31e2567233, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Dec 06 10:05:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666382, encodeId=2f46166638255, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Dec 12 15:05:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533477, encodeId=647a15334e752, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606320, encodeId=68bc16063206a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=)]
    2014-12-12 showtest
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725672, encodeId=73b31e2567233, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Dec 06 10:05:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666382, encodeId=2f46166638255, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Dec 12 15:05:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533477, encodeId=647a15334e752, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606320, encodeId=68bc16063206a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=)]
    2014-11-12 wleon8899
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725672, encodeId=73b31e2567233, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Dec 06 10:05:00 CST 2014, time=2014-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666382, encodeId=2f46166638255, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Dec 12 15:05:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533477, encodeId=647a15334e752, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14000, encryptionId=e59c1400060, topicName=PEG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbc812457783, createdName=wleon8899, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606320, encodeId=68bc16063206a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 12 00:05:00 CST 2014, time=2014-11-12, status=1, ipAttribution=)]

相关资讯

韩涛:肝性脑病治疗现状与思考

文章作者:天津市第三中心医院韩涛       肝性脑病(HE)是由于肝脏功能严重障碍和(或)门体分流引起的、以代谢紊乱为基础的中枢神经系统功能失调综合征,是终末期肝病常见并发症之一。近年来,HE临床治疗进展不大,要真正处理好HE仍有难度,而且不同研究的结论各异、甚至相互矛盾,许多问题尚无明确答案。为何会出现这种状况?值得深思。 

J. Hepatol.:肝硬化合并肝性脑病患者更易发生颅骨骨折

肝性脑病(HE)是肝硬化患者的可逆性神经精神疾病。由HE导致的认知障碍和意外跌倒的增加,以及肝硬化造成的骨营养不良,可能共同促进了骨折的发生。先前有关骨折发生风险的研究主要是小规模的病例对照研究,但缺少关于骨折发生率的信息和细节。对于骨折发生率、发生位置以及相关医疗成本的进一步研究,或许有助于设计更好的预防策略。基于上述情况,来自台湾国立阳明大学医学院及台北荣民总医院的医学博士Chia-Fen T

病例:慢性复发型肝性脑病1例

        病历报告   主诉 60岁男性,因“发热伴神志恍惚3天”入我院。   病史 患者有乙肝肝硬化失代偿和肝性脑病史,无饮酒史。自2004年以来,患者先后多次因肝性脑病在我科住院治疗。   本次发病前,患者出现咳嗽、咳痰;3天前发热伴神志恍惚,体温最高达38.6℃;无

AJG:利福昔明联用乳果糖治疗肝性脑病效果更佳

研究热点: 1.乳果糖是治疗肝性脑病的常规药物。利福昔明是近期研究证实能够有效控制肝性脑病症状的光谱抗生素。但对于两药联用治疗肝性脑病的效果及安全性目前仍缺乏相应研究。 2.作者在120名肝性脑病患者中进行了一项随机-对照-双盲的临床试验以评估利福昔明联合乳果糖治疗肝性脑病的安全性及临床效果。 3.联用利福昔明及乳果糖比单用乳果糖可获得更好的临床效果,能有效逆转患者症状、缩短住院时间、降